Literature DB >> 12654841

Pulmonary necrosis resulting from DNA vaccination against tuberculosis.

Jennifer L Taylor1, Oliver C Turner, Randall J Basaraba, John T Belisle, Kris Huygen, Ian M Orme.   

Abstract

The use of DNA constructs encoding mycobacterial proteins is a promising new approach to vaccination against tuberculosis. A DNA vaccine encoding the hsp60 molecule of Mycobacterium leprae has previously been shown to protect against intravenous infection of mice with Mycobacterium tuberculosis in both the prophylactic and immunotherapeutic modes. It is shown here, however, that this vaccine was not effective in a more realistic aerosol infection model or in a model of latent tuberculosis in the lungs. Moreover, when given in an immunotherapeutic model the immunized mice developed classical Koch reactions characterized by multifocal discrete regions of cellular necrosis throughout the lung granulomas. Similar and equally severe reactions were seen in mice given a vaccine with DNA coding for the Ag85 antigen of M. tuberculosis. This previously unanticipated safety problem indicates that DNA vaccines should be used with caution in individuals who may have already been exposed to tuberculosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12654841      PMCID: PMC152079          DOI: 10.1128/IAI.71.4.2192-2198.2003

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

Review 1.  Tuberculosis vaccine development: recent progress.

Authors:  I M Orme; D N McMurray; J T Belisle
Journal:  Trends Microbiol       Date:  2001-03       Impact factor: 17.079

2.  Spleen cell cytokine secretion in Mycobacterium bovis BCG-infected mice.

Authors:  K Huygen; D Abramowicz; P Vandenbussche; F Jacobs; J De Bruyn; A Kentos; A Drowart; J P Van Vooren; M Goldman
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

3.  Lack of protection in mice and necrotizing bronchointerstitial pneumonia with bronchiolitis in guinea pigs immunized with vaccines directed against the hsp60 molecule of Mycobacterium tuberculosis.

Authors:  O C Turner; A D Roberts; A A Frank; S W Phalen; D M McMurray; J Content; O Denis; S D'Souza; A Tanghe; K Huygen; I M Orme
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

4.  Enumeration of T cells reactive with Mycobacterium tuberculosis organisms and specific for the recombinant mycobacterial 64-kDa protein.

Authors:  S H Kaufmann; U Väth; J E Thole; J D Van Embden; F Emmrich
Journal:  Eur J Immunol       Date:  1987-03       Impact factor: 5.532

5.  Mycobacterial antigens exacerbate disease manifestations in Mycobacterium tuberculosis-infected mice.

Authors:  Andre L Moreira; Liana Tsenova; Melles Haile Aman; Linda-Gail Bekker; Sherry Freeman; Bande Mangaliso; Ulf Schröder; Jaishree Jagirdar; William N Rom; Michael G Tovey; Victoria H Freedman; Gilla Kaplan
Journal:  Infect Immun       Date:  2002-04       Impact factor: 3.441

6.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

Review 7.  The mycobacterial 65 kD heat-shock protein and autoimmune arthritis.

Authors:  W van Eden; E J Hogervorst; R van der Zee; J D van Embden; E J Hensen; I R Cohen
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

8.  DNA immunization in a mouse model of latent tuberculosis: effect of DNA vaccination on reactivation of disease and on reinfection with a secondary challenge.

Authors:  Charlene J Repique; Amy Li; Frank M Collins; Sheldon L Morris
Journal:  Infect Immun       Date:  2002-07       Impact factor: 3.441

Review 9.  T cell response to Mycobacterium tuberculosis.

Authors:  I M Orme; P Andersen; W H Boom
Journal:  J Infect Dis       Date:  1993-06       Impact factor: 5.226

Review 10.  Evaluation of the protective potency of new tuberculosis vaccines.

Authors:  E H Wiegeshaus; D W Smith
Journal:  Rev Infect Dis       Date:  1989 Mar-Apr
View more
  38 in total

Review 1.  On the use of DNA vaccines for the prophylaxis of mycobacterial diseases.

Authors:  Kris Huygen
Journal:  Infect Immun       Date:  2003-04       Impact factor: 3.441

2.  Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model.

Authors:  Eric Nuermberger; Sandeep Tyagi; Kathy N Williams; Ian Rosenthal; William R Bishai; Jacques H Grosset
Journal:  Am J Respir Crit Care Med       Date:  2005-09-08       Impact factor: 21.405

3.  Factors associated with severe granulomatous pneumonia in Mycobacterium tuberculosis-infected mice vaccinated therapeutically with hsp65 DNA.

Authors:  Jennifer L Taylor; Diane J Ordway; Jolynn Troudt; Mercedes Gonzalez-Juarrero; Randall J Basaraba; Ian M Orme
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

4.  Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol.

Authors:  Randall J Basaraba; Erin E Smith; Crystal A Shanley; Ian M Orme
Journal:  Infect Immun       Date:  2006-09       Impact factor: 3.441

5.  CBA/J mice generate protective immunity to soluble Ag85 but fail to respond efficiently to Ag85 during natural Mycobacterium tuberculosis infection.

Authors:  Gillian L Beamer; Joshua Cyktor; David K Flaherty; Paul C Stromberg; Bridget Carruthers; Joanne Turner
Journal:  Eur J Immunol       Date:  2012-04       Impact factor: 5.532

6.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

Authors:  Clare R Sander; Ansar A Pathan; Natalie E R Beveridge; Ian Poulton; Angela Minassian; Nicola Alder; Johan Van Wijgerden; Adrian V S Hill; Fergus V Gleeson; Robert J O Davies; Geoffrey Pasvol; Helen McShane
Journal:  Am J Respir Crit Care Med       Date:  2009-01-16       Impact factor: 21.405

7.  Ipr1 gene mediates innate immunity to tuberculosis.

Authors:  Hui Pan; Bo-Shiun Yan; Mauricio Rojas; Yuriy V Shebzukhov; Hongwei Zhou; Lester Kobzik; Darren E Higgins; Mark J Daly; Barry R Bloom; Igor Kramnik
Journal:  Nature       Date:  2005-04-07       Impact factor: 49.962

Review 8.  Mixed-strain mycobacterium tuberculosis infections and the implications for tuberculosis treatment and control.

Authors:  Ted Cohen; Paul D van Helden; Douglas Wilson; Caroline Colijn; Megan M McLaughlin; Ibrahim Abubakar; Robin M Warren
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

Review 9.  Mycobacterium tuberculosis-specific CD8+ T cells and their role in immunity.

Authors:  Joshua S M Woodworth; Samuel M Behar
Journal:  Crit Rev Immunol       Date:  2006       Impact factor: 2.214

10.  Granuloma necrosis during Mycobacterium avium infection does not require tumor necrosis factor.

Authors:  Manuela Flórido; Rui Appelberg
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.